## Prostate cancer
### Plenary Session 3

**Sunday 18 March**
**08:00 - 10:30**

**Location:** Green Area, eURO Auditorium (Level 0)

**Chairs:**
- F. Montorsi, Milan (IT)
- M. Wirth, Dresden (DE)

### Aims and objectives of this session
This initial part of the session aims to illustrate the level and availability of genomic information needed to risk classify profile tumours according to their genetic profile. The audience will understand why efforts are made to develop genetic tests, and what is needed to make this a clinical tool.

### 08:00 - 08:25
**Debate**
**Genomic screening before active surveillance - Enough data?**

**Moderator:** C.H. Bangma, Rotterdam (NL)

#### 08:00 - 08:10
**Genomic screening should be done**
M.R. Cooperberg, San Francisco (US)

#### 08:10 - 08:20
**Clinical data and imaging are doing the job**
O. Rouviere, Lyon (FR)

#### 08:20 - 08:25
**Discussion**

### 08:25 - 08:40
**European Society for Medical Oncology (ESMO) lecture**
**Metastatic castration-resistant prostate cancer (mCRPC)**
G. Attard, Sutton (GB)

### 08:40 - 09:35
**Case-based debate**
**Positron Emission Tomography–Computed Tomography (PET-CT) detected oligometastatic disease**

**Moderator:** A. Briganti, Milan (IT)

#### 08:40 - 08:45
**Case presentation**
A. Briganti, Milan (IT)

#### 08:45 - 08:55
**Systemic therapy is the standard of care**
S. Gillessen Sommer, St. Gallen (CH)

#### 08:55 - 09:05
**Local control is needed**
S. Joniau, Leuven (BE)

#### 09:05 - 09:15
**Local and metastasis imaging targeted treatments are needed**
G. De Meerleer, Ghent (BE)

#### 09:15 - 09:25
**The EAU Guidelines perspective**
N. Mottet, Saint-Étienne (FR)

#### 09:25 - 09:35
**Discussion**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 - 09:45</td>
<td>Highlights from the poster sessions</td>
<td>Androgen Receptor (AR) targeted therapy for non-metastatic Castration-Resistant Prostate Cancer (CRPC) M. De Santis, Coventry (GB)</td>
</tr>
<tr>
<td>09:45 - 10:30</td>
<td>Case-based debate</td>
<td>Locally advanced non-metastatic cancer in elderly patients Moderator: N.W. Clarke, Manchester (GB)</td>
</tr>
<tr>
<td>09:45 - 09:50</td>
<td>Case presentation</td>
<td>N.W. Clarke, Manchester (GB)</td>
</tr>
<tr>
<td>09:50 - 10:00</td>
<td>Geriatric assessment</td>
<td>A. Morgans, Nashville (US)</td>
</tr>
<tr>
<td>10:00 - 10:10</td>
<td>Systemic treatment</td>
<td>K. Fizazi, Villejuif (FR)</td>
</tr>
<tr>
<td>10:10 - 10:20</td>
<td>Local treatment</td>
<td>C. Cozzarini, Milan (IT)</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>